Referencias para literatura Línea Cardiometabólica Julio 27 2026

  • EZETIMIBA:
  1. Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 Nov 7;46(42):4359-4378.
  • COLESTOX-ROSUVASTATINA:
  1. Blumenthal RS, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.J Am Coll Cardiol. 2026;87(19):2624-2757;
  2. Stein EA, et al. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007;100(9):1387-1396.
  • RISCOL-ATORVASTATINA:
  1. Adams SP, et al. Atorvastatin for lowering lipids. Cochrane Database Syst Rev. 2015;(3):CD008226;
  2. Lee YJ, et al. Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial. BMJ. 2023;383:e075837.
  • COLESTOX + Ezetimiba:
  1. Leiter LA, et al. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008;102(11):1495-1501;
  2. Zhang YJ, et al. Effect of ezetimibe-statin combination therapy vs. statin monotherapy on coronary atheroma phenotype and lumen stenosis in patients with coronary artery disease: a meta-analysis and trial sequential analysis.Front Pharmacol. 2024;15:1343582;
  3. Ballantyne CM, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-680.
  4. Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).Am J Cardiol. 2007;99(5):673-680. doi:10.1016/j.amjcard.2006.10.022
  • RISCOL + Ezetimiba:
  1. Samir A, et al. Consistency over intensity: atorvastatin 40 mg plus ezetimibe 10 mg versus atorvastatin 80 mg in ACS patients: a comparative study of efficacy, tolerability, and cardiovascular outcomes. Egypt Heart J. 2025 Dec 12;77(1):110.
  • LOWCOL:
  1. Banach M, et al; Impact of Lipid-Lowering Combination Therapy With Statins and Ezetimibe vs Statin Monotherapy on the Reduction of Cardiovascular Outcomes: A Meta-analysis. Mayo Clin Proc. 2025 Dec;100(12):2152-2171;
  2. Mihaylova B, et al. Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP). Am J Kidney Dis. 2016 Apr;67(4):576-84;
  3. Chauhan D, et al. Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review. Cureus. 2022 Nov 2;14(11):e31007.
  • BECLAZONE:
  1. George R, et al. Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2022 Oct 1;40(10):1876-1886;
  2. Barrett ME, et al. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol. 2013;149(3):300-306;
  3. Kiefer MK, Williams H, Nwosu O, Doan Mast DD, Costantine MM, Rood KM. Daily Versus BID Nifedipine GITS in Severe Preeclampsia: Randomized Controlled Trial. Hypertension. 2025 Sep;82(9):1421-1429;
  4. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Nifedipine. [Updated 2025 Nov 15];
  5. Close Up / IQVIA (Nancy: Indicar qué mes, qué año)
  • TENSOFAR:
  • Moya L et al. Consenso de expertos sobre el manejo clínico de la hipertensión arterial en Colombia. Sociedad Colombiana de Cardiología y Cirugía. Rev Colomb Cardiol. 2018;25(S3):4-26
  • TENSOFAR H:
  1. Xie M, et al. Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis. Clin Cardiol. 2023; 46(8):886-898;
  2. Okura T, et al. Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension. Clin Exp Hypertens. 2013;35(8):563-9.
  • ALIDONA:
  1. Jones DW, et al. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567-1678;
  2. Mafrica D, Franculli G, Esposito A, Sarto G, Sabouret P, Biondi-Zoccai G, et al. Chronic coronary syndromes: diagnosis, management and gaps in evidence. Heart Vessels Transplant. 2024;8(3):391-410.;
  3. Wang JG, et al. Amlodipine in the current management of hypertension. J Clin Hypertens (Greenwich). 2023; 25(9):801-807.
  • ALIDONA IR:
  1. Writing Committee Members*, Jones DW, Ferdinand KC, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2025;152(11):e114-e218;
  2. McEvoy JW, McCarthy CP, Bruno RM, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.
  • SCRIPTENE:
  • Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol. 2007 Aug;151(7):952-62;
  • Neutel J, Elliott WJ, Izzo J, Chen CL, Masonson H. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (Greenwich). 2002;4(5):325-331;
  • Albayrak S, Ordu S, Ozhan H, et al. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Blood Press. 2009;18(4):187-191. doi:10.1080/08037050903047236
  • ALIDOTEL:
  • Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol. 2011 Sep-Oct;24(5):569-80.
  • VILDAGLIPTINA:
  1. He YL, Ligueros-Saylan M, Sunkara G, et al. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects. J Clin Pharmacol. 2008;48(1):85-95;
  2. European Medicines Agency.EPAR—Product information. Amsterdam: European Medicines Agency; updated January 29, 2025. Section 4.5, Interaction with other medicinal products and other forms of interaction.
  • SITAGLIPTINA:
  1. Green JB, Bethel MA, Armstrong PW, et al; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232-242;
  2. Barchetta I, Filardi T, Dule S, et al. Effect of sitagliptin vs. placebo on bone mineralization in women with type 2 diabetes: the SLowDOWN (SitagLiptin in Diabetes for Osteoporosis in WomeN) randomized clinical trial. BMC Med. 2025;23(1):562;
  3. Abbatecola AM, Maggi S, Paolisso G. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies. Drugs Aging. 2008;25(11):913-925. doi:10.2165/0002512-200825110-00002
  • ASA:
  1. U.S. Preventive Services Task Force. Acetylsalicilic acid use to prevent cardiovascular disease: US Preventive Services Task Force recommendation statement. JAMA. 2022;327(16):1577-1584;
  2. Virani SS, et al. & Peer Review Committee Members. 2023 AHA/ ACC/ ACCP/ ASPC/ NLA/ PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023 Aug 29;148(9):e9-e119;
  3. Lawton JS, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 Jan 18;145(3):e18-e114;
  4. Kleindorfer DO, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2021 Jul;52(7):e364-e467; 5. Naylor R, et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023 Jan;65(1):7-111.
  • DENSIMET:
  1. Demay MB, et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2024 Jul 12;109(8):1907-1947;
  2. Qi KJ, Zhao ZT, Zhang W, Yang F. The impacts of vitamin D supplementation in adults with metabolic syndrome: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2022;13:1033026;
  3. Gagnon C, et al. Low serum 25-hydroxyvitamin D is associated with increased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab). J Clin Endocrinol Metab. 2012;97(6):1953-1961;
  4. Barale M, Rossetto Giaccherino R, Ghigo E, Procopio M. Effect of 1-year oral cholecalciferol on a metabolic profile and blood pressure in poor-controlled type 2 diabetes mellitus: an open-label randomized controlled pilot study. J Endocrinol Invest. 2021;44(4):791-802; 5. Información en Archivo Novamed.
  • LIPOGRAS:
  1. Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA.2024;332(7):571–584;
  2. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56(1):82-85. doi:10.1038/clpt.1994.104;

3. Chilton M, Dunkley A, Carter P, Davies MJ, Khunti K, Gray LJ. The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes Obes Metab. 2014;16(3):237-247. doi:10.1111/dom.12198

Scroll al inicio